July 12, 2005 The Centient Biotech 200 came within a nose of its best level of the year, moving up 20 points to 3540.93, a rise of .57%. That was within one point of its final print on January 3, the first trading session of the year and the highest closing price so far in 2005. Amgen and Genentech both hit 52-week highs after Genentech reported Q2 earnings and as Amgen is about to do the same, Biopure must answer FDA questions before starting a trial of its bovine hemoglobin, Pharmacopeia will partner with Allergan on a wet age-related macular degeneration drug, Nabi Pharma reported good data on StaphVAX following cardiovascular surgery, Aphton said its targeted therapy for ephithelia tumors looks good in early tests, Intrac reported Dyloject showed non-inferiority in a pain trial, and ID Biomedical won Fast-Track designation for its flu vaccine. More details...
